Daniel Burch, M.D., serves as the global medical officer for PPD® Biotech. Dr. Burch joined the PPD organization in 2012, initially to lead the company’s neuroscience product development function. He was named global medical officer of PPD Biotech in 2016.
Prior to coming to PPD, he served as executive vice president and chief medical officer at CeNeRx BioPharma, a venture-backed, clinical-stage biotech, where he managed a portfolio of medicines focused on neuropsychiatric diseases. Prior to that, he headed the Neuroscience Medicines Development Centre at GlaxoSmithKline where he had global responsibility for Phase II development through lifecycle management.
Earlier in his career at GSK and Abbvie, Dr. Burch held roles of increasing responsibility in a variety of global R&D and regional medical affairs functions across multiple therapeutic areas. Having worked for more than 25 years in many aspects of drug development, Dr. Burch has set a personal goal to most efficiently promote and facilitate the development of medicines in areas of highest unmet need.
Dr. Burch earned his medical degree from the Vanderbilt University School of Medicine, where he completed a residency in internal medicine. Subsequently, he completed a fellowship and post-doctoral research in infectious diseases at Washington University School of Medicine. He earned his MBA at the University of Pennsylvania’s Wharton School and currently serves on the Institute of Medicine Forum on Neuroscience and Nervous System Disorders.